Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 February 2025, European Medicines Agency, Amsterdam, the Netherlands, from 10 February 2025 to 13 February 2025

Submitted by Anonymous (not verified) on 10 February 2025 - 15:51

Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 February 2025, European Medicines Agency, Amsterdam, the Netherlands, from 10 February 2025 to 13 February 2025

Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance

Submitted by Anonymous (not verified) on 10 February 2025 - 13:40

Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness